myeloblast


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to myeloblast: myeloblastic leukemia

my·e·lo·blast

 (mī′ə-lə-blăst′)
n.
An immature cell of the bone marrow that is the precursor of a myelocyte.

my′e·lo·blas′tic adj.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

myeloblast

(ˈmaɪələʊˌblɑːst)
n
(Pathology) a cell that gives rise to a granulocyte, normally occurring in the bone marrow but detected in the blood in certain diseases, esp leukaemia
myeloblastic adj
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.myeloblast - a precursor of leukocytes that normally occurs only in bone marrow
leucocyte, leukocyte, WBC, white blood cell, white blood corpuscle, white cell, white corpuscle - blood cells that engulf and digest bacteria and fungi; an important part of the body's defense system
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
Translations

my·e·lo·blast

n. mieloblasto, una célula no madura en la serie granulocítica, generalmente presente en la médula ósea.
English-Spanish Medical Dictionary © Farlex 2012
References in periodicals archive ?
It is tempting to speculate that in the absence of signals required for differentiation of the granulocytic lineages, the monocytic lineage is the default route of differentiation for the myeloblast. Thus, the gain of extra chromosome 8's may cause a block in the differentiation route of granulocytes, skewing cells towards a default myelomonocytic pathway.
Neutrophils derived from bone marrow hematopoietic stem cells, which undergoes multiple developmental stages, such as myeloblast, premyelocyte, myelocyte, metagranulocyte, band neutrophils, and eventually develop into mature neutrophils.
They analyzed the proteases and protease inhibitors in uEVs isolated by hydrostatic dialysis and demonstrated an increase of myeloblast and its natural inhibitor in the normal- and microalbuminuria groups.
Megakaryocytes count was performed under 10x magnification whereas the other cell counts (rubriblite, prokaryotic, rubricito, metarrubic, myeloblast, promyelocyte, metamielocyte, myelocyte, rodent, eosinophils, basophils, neutrophil, lymphocyte, plasma cell, and monocyte counts) were done using the 100x objective with oil immersion.
Laboratory investigations showed haemoglobin 5.7gm./dl; Total leukocyte count 614.8x10 9 /l, Myeloblast 65%, Promyelocytes 10%, Myelocytes 26%, Metamyelocytes 18%, Band cells 4%, Neutrophils 30% and Lymphocytes 7%: ESR 2mm, platelets 709x10 12 /L.
Ribonuclease-free deoxyribonuclease-treated total RNA (1.0 [micro]g) was reverse-transcribed with Aves myeloblast leukemia virus reverse transcriptase (Promega).
Immune cell production of cytokines such as tumor necrosis factor-[alpha] (TNF-alpha) and interferon-[gamma] (IFN-gamma) has been shown to directlyinhibit myeloblast proliferation [34, 35].
Treatment of leukemia cell lines with ezatiostat has been demonstrated to induce myeloblast differentiation without affecting myelopoiesis [94].
Maturation stages in the bone marrow are as follows: stem cell, myeloblast, promyelocyte, myelocyte, metamyelocyte, band and neutrophil.
Leukemic cell lines Name Morphology [IC.sub.50] ([micro]g/ml) MOLT3 (a) Lymphoblast 17.20 [+ or -] 2.22 K562 (a) Lymphoblast 18.10 [+ or -] 0.95 HL-60 (a) Myeloblast 12.70 [+ or -] 0.10 U937 (b) Monocytes 12.7 [+ or -] 0.46 Solid tumor cell lines (a) Name Morphology [IC.sub.50] ([micro]g/ml) MCF7 Epithelial 32.95 [+ or -] 1.63 A549 Epithelial 55.26 [+ or -] 5.90 HepC2 Epithelial 28.10 [+ or -] 0.58 (a) Cells (5 x [10.sup.4]/200 [micro]l) were treated with MAL-A (0-100 [micro]g/ml) for 48 h and cell viability was measured as described in Materials and methods.
NRP-1 expression was directly correlated with myeloblast percentage in the bone marrow of patients with AML, suggesting that NRP-1 correlates with tumor load.